GenFleet: GenFleet: building a fleet of first-in-class cancer and immune therapies

DEC 07, 2023 | 3:34 PM PST | BIOCENTURY | EMERGING COMPANY PROFILEGENFLEET: BUILDING A FLEET OF FIRST-IN-CLASS CANCER AND IMMUNE THERAPIESBY With its first regulatory submission filed in China, the biotech is setting its next sights on global first-in-class therapieshttps://www.biocentury.com/article/650049/genfleet-building-a-fleet-of-first-in-class-cancer-and-immune-therapies© 2023 BioCentury Inc. All Rights Reserved